RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$141.01
-2.59 (-1.80%)
▼
5d:
+6.86%
30d:
+1.45%
90d:
+19.19%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 2.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 2.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$78.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $141.01, which is considered fair relative to its 30-day fair value range of $134.33 to $146.48. The stock's valuation (Forward PE: 54.7) is in line with its historical norms (58.6). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This pessimistic expectation contrasts with the company's recent 47.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $129.00, while resistance sits at $154.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $182.05 (+28.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $129.00, while resistance sits at $154.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $182.05 (+28.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$134.33 -
$146.48
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.9% below Wall St target ($182.05)
Trading Range Analysis
30-Day Trading Range
$134.33 -
$146.48
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$129.00
Resistance Level
$154.00
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
54.70
Wall Street Target
$182.05
(+28.9%)
Revenue Growth (YoY)
14.8%
Earnings Growth (YoY)
47.9%
Profit Margin
6.7%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
54.7 vs 58.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$137.98
(-2%)
2-Year Target
$134.81
(-5%)
3-Year Target
$131.71
(-7%)
3-Yr Target (if PE normalizes)
(PE: 55→59)
$141.10
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 54.7, Growth: 25.6%)
$279.77
(+98%)
Base:
(SPY PE: 20.8, Growth: 25.6%)
$106.44
(-25%)
Bear:
(PE: 17.7, Growth: 25.6%)
$90.47
(-36%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (66x PE), but valuation improves significantly next year (55x PE) as earnings recover.
Forward PE: 66.23 | Forward EPS (Implied): $2.13
Bull Case
$170.27
(+21%)
Analyst growth 15.0%, PE expands to 69.5
Base Case
$141.01
(0%)
Market implied 0.0%, PE stable at 66.2
Bear Case
$107.87
(-24%)
Severe decline -15.0%, PE contracts to 59.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 54.7 to 58.6
Stabilization Target:
$151.30
(+7.1%)
PE Expansion Potential:
+7.1%
Share & Embed Analysis
Last updated: August 02, 2026 6:12 PM ET
Data refreshes hourly during market hours. Next update: 7:12 PM
Data refreshes hourly during market hours. Next update: 7:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$477 | 47 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$87 | 50 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 56 HOLD |
|
AVTR
Avantor Inc |
HOLD
21 analysts |
$15 | 56 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$249 | 49 HOLD |
